Clinical trials: Diarrhea Predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome With Diarrhea
Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).
The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients.
- Trial name
- NCT06153420
- Testing
- CIN-103
- Where
- 53 sites in United States
- Volunteers
- 421 people
- Sponsor
- CinPhloro Pharma, LLC
Diarrhea Predominant Irritable Bowel Syndrome
Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids
The investigators' hypothesis is that therapy with Colesevelam, reduces fecal bile acid excretion in patients with Irritable Bowel Syndrome (IBS)-diarrhea with prior evidence of increased fecal 48 hour total bile acid excretion.
- Trial name
- NCT02111603
- Testing
- Colesevelam
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mayo Clinic
IBS, Diarrhea Predominant
Transcutaneous Electrical Acustimulation for IBS-D: A Multicenter Study
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent abdominal pain and altered bowel habits.
- Trial name
- NCT07425145
- Testing
- Portable stimulator
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First People's Hospital of Foshan
IBS-C and IBS With Mixed Bowel Habits
Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS
Recent literature has demonstrated that the group of IBS sufferers who experience mixed bowel habits may be more similar to IBS-C patients than IBS-D patients.
- Trial name
- NCT00142987
- Testing
- Tegaserod
- Volunteers
- 664 people
- Sponsor
- Novartis
Non-erosive Reflux Disease, Diarrhea-Predominant Irritable Bowel Syndrome
Efficacy and Safety of WPQW Granule for Overlap of NERD and IBS-D
Non-erosive reflux disease（NERD）and Diarrhea-Predominant Irritable Bowel Syndrome（IBS-D）are both the common refractory gastrointestinal diseases.
- Trial name
- NCT05369884
- Testing
- WPQW granule, WPQW granule simulant
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
IBS - Irritable Bowel Syndrome, Gut Microbiota
Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D
We will use the latest Rome IV criteria to recruit IBS-D patients and evaluate the effects of repeated treatment with rifaximin and sequential treatment with rifaximin and probiotics on different symptoms and quality of life.
- Trial name
- NCT04074421
- Testing
- Rifaximin, Probiotic Formula
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Irritable Bowel Syndrome
Multi-strain Probiotic in the Management of IBS-D
1. To assess the effect of multistrain probiotics on abdominal pain using a validated symptom severity score in IBS patients. 2.
- Trial name
- NCT03251625
- Testing
- Probiotic Formula Capsule
- Volunteers
- 400 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of JNJ-27018966 (eluxadoline) compared with placebo in the treatment of patients with irritable bowel syndrome with diarrhea…
- Trial name
- NCT01130272
- Testing
- Eluxadoline
- Where
- 288 sites in United States
- Volunteers
- 807 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Irritable Bowel Syndrome (IBS), Irritable Bowel Syndrome With Diarrhea (IBS-D)
Curcumin, Vitamin D and Green Tea in IBS-D
Irritable Bowel Syndrome (IBS) is a highly prevalent condition of the gastrointestinal tract that has significant impact on sufferer's quality of life. The diarrhoea variant (IBS-D) makes up around one third of all IBS sufferers.
- Trial name
- NCT07052890
- Testing
- Curcumin, vitamin d and green tea extract
- Where
- 3 sites in United Kingdom
- Volunteers
- 78 people
- Sponsor
- Dr Anthony Hobson
Irritable Bowel Syndrome
Efficacy and Safety of Chinese Medicine JCM-16021 for Diarrhea-predominant Irritable Bowel Syndrome
This is a multicenter, randomized, double-blind, placebo controlled clinical trial, in order to evaluate the efficacy and safety of Chinese Medicine JCM-16021 for diarrhea-predominant irritable bowel syndrome.
- Trial name
- NCT03457324
- Testing
- JCM-16021
- Where
- 2 sites in China
- Volunteers
- 392 people
- Sponsor
- ZhaoXiang Bian
Irritable Bowel Syndrome
Gluten-free Diet in Irritable Bowel Syndrome
To evaluate the effects of a gluten-free diet in irritable bowel syndrome.
- Trial name
- NCT02528929
- Testing
- Gluten-free diet
- Volunteers
- 48 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Diarrhea-Predominant Irritable Bowel Syndrome
Glutamine for the Treatment of Patients With Irritable Bowel Syndrome
New and effective treatments are needed for patients with post-infectious irritable bowel syndrome (PI-IBS). We conducted a randomized, placebo-controlled trial to assess the efficacy and safety of glutamine, an abundant amino…
- Trial name
- AT005291 (NCT01414244)
- Testing
- Glutamine
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Tulane University
Diarrhea-predominant Irritable Bowel Syndrome
Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D
To evaluate the safety and effectiveness of oral nutritional therapy Serum-Derived Bovine Immunoglobulin (SBI) on nutritional status, epithelial barrier function, and mucosal expression of pivotal genes including tight junction…
- Trial name
- NCT02163213
- Testing
- Serum-derived bovine immunoglobulin protein isolate (SBI)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Diarrhea Predominant Irritable Bowel Syndrome
A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
This trial will evaluate the effect of ASP7147 on daily abdominal pain due to IBS-D during 4 weeks of treatment. It will also evaluate safety and tolerability in patients with IBS-D over the 4-week treatment period.
- Trial name
- NCT01896583
- Testing
- ASP7147
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Seldar Pharma, Inc.
Irritable Bowel Syndrome With Diarrhea
Study on the Molecular Mechanism of Diarrhea-predominant Irritable Bowel Syndrome With Anxiety and Depression Based on Multi-omics Correlation Analysis
The research group intends to carry out a case-control study to recruit IBS-D patients with anxiety and depression symptoms, by collecting intestinal mucosa for single-cell transcriptome sequencing, collecting peripheral blood…
- Trial name
- NCT05311293
- Testing
- Endoscopy
- Where
- China
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Tang-Du Hospital
Irritable Bowel Syndrome
A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients
A study to verify the superiority of YM060 (ramosetron) to placebo for female patients with diarrhea-predominant irritable bowel syndrome (D-IBS) and to evaluate its safety.
- Trial name
- NCT01274000
- Testing
- YM060
- Where
- 4 sites in Japan
- Volunteers
- 409 people
- Sponsor
- Astellas Pharma Inc
IBS-D (Diarrhea-predominant)
Study to Evaluate the Treatment Benefits of Probiotic Clostridium Butyricum CBM588® for IBS-D
Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder affecting 15-20% of people in industrialized countries, often presenting as abdominal discomfort, pain, and altered bowel habits, significantly impacting…
- Trial name
- PROREDI (NCT06676514)
- Testing
- Probiotic Clostridium butyricum CBM588®, Standard of care IBS-D treatment
- Where
- Italy
- Volunteers
- 405 people
- Sponsor
- Liaquat University of Medical & Health Sciences
Diarrhea Predominant Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth
The primary objective of this study is to determine whether giving SBI as a medical food starting with maintenance of health in the management of chronic loose and frequent stools in IBS-D subjects with SIBO after successful…
- Trial name
- NCT02251483
- Testing
- Serum-derived bovine immunoglobulin protein isolate (SBI)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Cedars-Sinai Medical Center
Diarrhea Predominant Irritable Bowel Syndrome
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
The purpose of this study is to determine whether asimadoline is safe and effective at treating D-IBS.
- Trial name
- NCT01100684
- Testing
- Asimadoline
- Where
- 142 sites in United States
- Volunteers
- 611 people
- Sponsor
- Tioga Pharmaceuticals
Irritable Bowel Syndrome With Diarrhea
The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome
IBS is a disorder of movement in the gut. People who have IBS may have diarrhea, constipation, or alternating bouts of both. IBS is not caused by injury or illness.
- Trial name
- NCT02431533
- Testing
- PX0612, Di-Calcium Phosphate
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Pharmabiotix Inc